{"_id":"zfWmweZ4JJn7gPfRtgxpsq6VLuEB3dzNr3WLaq103cJqWCavy995zS","lastupdate":"2023-10-23T00:00:00.000Z","update_date":"2023-10-23T00:00:00.000Z","lastModified":"Apr 24, 2025","active":1,"confidence_score":83,"confidence_score_reason":"sector, funding rounds, markets, not claimed","urlname":"cnbx-pharmaceuticals","minimal_profile":null,"status":"Public","fullstatus":"Public on OTC on Sep, 2017;","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$D5RItxDnLG7QqEhcTOUXY7dHyIQqqSA6DUClUeIr5fTylN1pzdBhNo.jpeg","name":"CNBX Pharmaceuticals","oneliner":"Cnnabinoid-based Cancer Therapies","registrar":"515125557","website":"https://cnbxpharma.com/","careerspage":"","founded_month":1,"founded_year":2004,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/CNBXPharma","youtube":"https://www.youtube.com/channel/UCDv3HpZ8hXk3ezhKmzqx8dA","facebook":"","linkedin":"https://www.linkedin.com/company/2878012","instagram":""},"social":["https://twitter.com/CNBXPharma","https://www.linkedin.com/company/2878012","https://www.youtube.com/channel/UCDv3HpZ8hXk3ezhKmzqx8dA","https://twitter.com/CNBXPharma"],"flattenedsociallinks":"https://twitter.com/CNBXPharma|https://www.linkedin.com/company/2878012|https://www.youtube.com/channel/UCDv3HpZ8hXk3ezhKmzqx8dA|https://twitter.com/CNBXPharma","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"1-10","employees_exact":7,"patent":null,"raised":0,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":null,"about":"CNBX Pharmaceuticals is developing a platform that leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based cancer therapies tailored to each patients specific profile. By developing tools to assess effectiveness on a personalized basis, Cannabics seeks to make cannabinoids part of the future of cancer therapy.\n\nCNBX Pharmaceuticals operates In Israel as G.R.I.N Ultra Ltd  where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.","climatetech_description":null,"is_climatetech_relevant":null,"phone":null,"country":null,"address":{"israeli":[{"id":"QovQcYbRStHK1u0neXEL9d88vAGkVxZrEVOSPDlQ0zlOORKcpLlzu9","city":"Tel Aviv-Yafo","type":null,"address":"HaBarzel St 11, Tel Aviv-Yafo, 6971017, Israel","placeid":"ChIJ92zRl5NJHRURCIj465Vp6XU","notactive":null,"openeddate":null,"registrarid":null,"firstrdcenter":null,"registrarname":null}],"officesabroad":[{"id":"7CFoKV6zcCQ8jUENnIUTmJjrIQI2yXbc6NisroAjRhhkuv1tjyNkgj","city":null,"address":"Maryland, USA","country":"United States","placeid":"ChIJ35Dx6etNtokRsfZVdmU3r_I"}]},"headquarter_address":null,"district":null,"news":[{"id":"U4gQkWuLb49g1BqCleh9YBHClh74RMVrScE3RodxjSSqTsvVpXnwl9","date":"Oct 13, 2022","link":"https://www.prnewswire.com/news-releases/cnbx-patent-application-composition-and-method-for-treating-cancer-with-cannabinoids-enters-national-phase-in-us-and-israel-301648446.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Patent Application, Cancer Treatment","company":"CNBX Pharmaceuticals Inc.","layoffs":"N/A","summary":"CNBX Pharmaceuticals Inc., a global leader in the development of cancer-related cannabinoid-based medicine, has filed a patent application titled COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS with the US Patent and Trademark Office and the Israel Patent Office on October 12, 2022. The patent application is related to several drug candidates in the companys pipeline for treating various types of cancer. The companys growing IP portfolio includes 8 patent families, with 7 granted patents and 18 additional pending.","partners":"N/A","customers":"Cancer Patients","investors":"N/A","confidence":9,"key_topics":["Patent Application","Cancer Treatment","Cannabinoid-Based Medicine","IP Portfolio","Clinical Research"],"date_of_event":"October 12, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EiYnnfZadYT0oNwxt1aZxcgnXnoq1PqKoJDSZLbAVwlsoQlTiwzhA9","news_summary":"CNBX Patent Application \"Composition and Method for Treating Cancer with Cannabinoids\" Enters National Phase in US and Israel","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"CTy33XayRInGl1k671Fr1wLZFN81eZzg7nL04UmoM09En3zMnXpHZb","date":"Mar 28, 2022","link":"https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-changes-name-to-cnbx-pharmaceuticals-301511565.html?fbclid=IwAR3pIiugTqMart2rYZv44Q-oeT-5imWJwggirhkqrQYf1CMH0BN0aKIDGhM","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Rebranding","company":"Cannabics Pharmaceuticals Inc.","layoffs":"N/A","summary":"Cannabics Pharmaceuticals Inc., a global leader in the development of cancer-related cannabinoid-based medicine, has announced a change in its corporate name to CNBX Pharmaceuticals Inc. The rebranding reflects the companys transformation and its forward-looking approach to molecule-based drug development for the treatment of colorectal cancer. The company is also preparing for a Phase I/II clinical validation study for its proprietary RCC-33 drug candidate. The companys stock will continue to trade under the ticker OTCQB: CNBX, and the change does not affect the rights of the companys stockholders.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Corporate Name Change","Cannabinoid-based Medicine","Cancer Treatment","Drug Development","Clinical Study"],"date_of_event":"April 1st, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cNchuauq3FTmHgVjsKdvoV4TLNVCfjp2IMl5GOAdhzcTyIcuHUm7fk","news_summary":"Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dovEW11ilfIrsMChMMvXkwwNNefCVP1wle5XFJUcOGjx1hjdnJkiSH","date":"Jun 13, 2020","link":"https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-to-capitalize-on-israels-final-approval-for-the-export-of-medical-cannabis-301064995.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Regulation, Export","company":"Cannabics Pharmaceuticals Inc.","layoffs":"N/A","summary":"Cannabics Pharmaceuticals Inc., a US-based company focused on personalized cannabinoid medicine for cancer, has received final approval from the Israeli government to export medical cannabis and products into international regulated markets such as the EU, Canada, and Australia. The new regulation will allow the export of GMP certified cannabis products under the Cannabics™ brand, such as Cannabics™ SR formulation, which has been tested as a palliative treatment for advanced cancer patients suffering from Cancer Anorexia-Cachexia Syndrome (CACS).","partners":"N/A","customers":"EU, Canada, Australia","investors":"N/A","confidence":9,"key_topics":["Medical Cannabis","Export Approval","International Markets","Cancer Treatment","Regulation"],"date_of_event":"May 26, 2020","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UQOLTgf7GBzH9C9CKixz9ncv9aAERCZQ0h1LELytBjr2BHZ5eYXfAx","news_summary":"Cannabics Pharmaceuticals to Capitalize on Israel's Final Approval for the Export of Medical Cannabis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"IcYJ411MU9y9dClo7YTTrvgp0WHaTAid0bcQyoa4QksLmkOWCoidSw","date":"May 10, 2020","link":"https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-shows-specific-cultivars-identified-to-have-positive-anti-tumor-effects-on-gastric-adenocarcinoma-301021398.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Research, Cancer Treatment","company":"Cannabics Pharmaceuticals Inc.","layoffs":"N/A","summary":"Cannabics Pharmaceuticals Inc., a leader in personalized cannabinoid medicine focused on cancer and its side effects, has completed a scan of selected RCKMCs cannabis strains. The results showed that two specific strains demonstrated higher anti-tumor activity. The strains were examined at the companys High Throughput Screening (HTS) facility located in Israel. The results will be used to further breed the selected cultivars for specific cancers, focusing on Gastric cancers. The cultivars to be developed will be the source for active pharmaceutical ingredients (APIs) for future clinical studies.","partners":"RCKMC","customers":"N/A","investors":"N/A","confidence":9,"key_topics":"Cannabis Strains, Anti-Tumor Activity, Gastric Cancers, Clinical Studies, Cannabinoid Medicine","date_of_event":"March 11, 2020","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Investment, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BWB949HGEUo8u79ja96UPu17Kpf5OaVQVXmDs6VRbRmwdBKQDLmk0f","news_summary":"Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3ZzWsQjy7nOZf4km8TCJNNgjnW4kEmzqJtk5zHrvakX6lrkMhCoDaN","date":"Dec 11, 2018","link":"","source":"","visible":1,"analysis":null,"sentiment":null,"analysisId":"VwiaKc2W5EYNXZTQFmMso5ajkqFqsuZ157bC8WqRvGBXuNF59jlv0L","news_summary":"Cannabics Pharmaceuticals Prepares ISO Application for Its Diagnostics Platform Towards Commercialization","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"hYktnNM9s58upueeJAihYgEeQ3zXJjCVtFiAioo3ib5tAjBD3rT4hU","date":"Feb 26, 2016","link":"https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-places-ip--subsidiary-within-the-company-300227523.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Investment, Intellectual Property","company":"Cannabics Pharmaceuticals Inc.","layoffs":"Not mentioned","summary":"Cannabics Pharmaceuticals Inc. has announced that it has placed its wholly owned subsidiary Grin Ultra Ltd. and all accompanying Intellectual Property rights into its public company. The Intellectual Property involves the companys IP filed with the USPTO entitled A Method of in Vitro High Throughput Screening of Cancer Biopsies with Cannabinoid Extracts. This system analyzes cancer cells taken directly from patient biopsies, and then tests them against a multitude of cannabinoid combinations for anti-tumor activity. Grin Ultra Ltd. is specifically licensed by the Israeli Health Ministry for cannabinoid research.","partners":"Not mentioned","customers":"Not mentioned","investors":"Aloni-Haft Group","confidence":9,"key_topics":["Cannabinoid Research","Investment","Intellectual Property","Subsidiary","Cancer Treatment"],"date_of_event":"Feb. 29, 2016","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iH1NMjR2QoYOOgLWVnL6ONhkBFLMTxy7VqM5gHWuGJYBGOvXSH87ke","news_summary":"Cannabics Pharmaceuticals Places IP & Subsidiary Within the Company","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":6,"techcommunityinvolvement":null,"mediagallery":[{"id":"Y6Wp7rUqQC6B1xn3bRBxBf3BzaWE8vaQEse2ki0mwzdaHLVdigbnwy","timestamp":"2023-10-23 08:23:46.000000","resources_type":2,"resources_title":"Introduction to Cannabics Pharmaceuticals Inc. Lab","resources_file_name":"mte263r7nFA","alt":"Introduction to Cannabics Pharmaceuticals Inc. Lab logo","imageurl":"https://img.youtube.com/vi/mte263r7nFA/0.jpg","url":"http://youtu.be/mte263r7nFA"}],"tags":["cancer","medical-cannabis","oncology"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":[],"geomarkets":[],"targetmarkets":[],"marketcapital":37005,"marketcapitaldate":"2025-11-01T14:09:40.000Z","funding":{"investors":0,"lastfunding":"Undisclosed","totalrounds":1,"fundingstage":"Public","totalfunding":"Undisclosed","publicinvestors":0,"lastpublicfunding":0,"totalpublicrounds":1,"totalpublicfunding":0},"team":[{"name":"Eyal Barard","email":"eyalbarad@cannabics.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Nj-poELDA","bounced":false,"claimed":null,"founder":0,"urlname":"eyal-barad","visible":1,"memberid":"zILE2XlJJT2ajJ4aOMmFlyZRLGbv6Ynhu90W0wRQySHMFQbM2w4ptx","position":"Co-Founder & CEO","last_name":"Barard","claimtoken":null,"first_name":"Eyal","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/eyalbarad/","unsubscribed":false,"is_activeuser":1,"additionalemail":"ebarad@cannabics.com","claimedemaildate":null,"initials":"EB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Eyal Ballan","email":"","phone":"0508619215","gender":"Male","userid":"wPk0PhBOiO6jAVqoOGPYCP7373eC9LzQPsBnC0vHSZlwfYBBSHvO8y","bounced":false,"claimed":null,"founder":1,"urlname":"eyal-ballan-1","visible":1,"memberid":"CDotsKADnhOTxItEKv3x4S2SUpqrJxbZePI6lM9bhMLMV709RoVgVx","position":"Co-founder (No longer with the company)","last_name":"Ballan","claimtoken":null,"first_name":"Eyal","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"EB","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Zohar Koren","email":"","phone":"","gender":"Male","userid":"XrjKJPaXae1QapxwTAIryCsfhBLCVg22HccAA9fMhtUx9bbZA7iNIf","bounced":false,"claimed":null,"founder":1,"urlname":"zohar-koren","visible":1,"memberid":"WqFhIGGsOmzRN9HTohVdmfPfPPQ8D51jBrfwxufD73ppMQgpOfkUaS","position":"Co-founder (No longer with the company)","last_name":"Koren","claimtoken":null,"first_name":"Zohar","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"ZK","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Itamar Borochov","email":"","phone":"","gender":"Male","userid":"YTRk6iQwE2IBc11KF1SWj2UkXwmhWODEFLcOnXTVzOwR68dZQ3aS4t","bounced":false,"claimed":null,"founder":1,"urlname":"itamar-borochov","visible":1,"memberid":"orej4n6XTI0Mdsb6gdUWYXLaz0GtPMrhD9Zfcyp5KBaJ3rtOvU9OxB","position":"Co-founder (No longer with the company)","last_name":"Borochov","claimtoken":null,"first_name":"Itamar","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"IB","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":null,"tag_line_edited":null,"sector":null,"sectorverify":null,"biverify":{"id":"7JMVZ1cDkplo2zZFEs4WRWhuj0xt9r8fRw5ZIjvtKeO50MH4vxhFbX","fullname":"Maor Perlov"},"biverifydate":"2023-10-23T00:00:00.000Z","crunchbaseid":null,"lastupdator":null,"lastupdator_email":null,"creator":"Maor Perlov","creator_email":"maor.perlov@sncentral.org","createdate":"2023-10-23T00:00:00.000Z","biverification":"Maor Perlov","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"DovXt9Dl6cYaCLeAehZL3PWXEnbjVKoEF7YF6vRSEcNrTv92xPLx6I","date":"Sep 2017","amount":"Undisclosed","source":"","ticker":"CNBX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"OTC","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCI2oTbCgw","stockexchange_logokey":"$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/2004","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"CNBX Pharmaceuticals","logourl":"https://storage.googleapis.com/clean-finder-353810/$D5RItxDnLG7QqEhcTOUXY7dHyIQqqSA6DUClUeIr5fTylN1pzdBhNo.jpeg","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$D5RItxDnLG7QqEhcTOUXY7dHyIQqqSA6DUClUeIr5fTylN1pzdBhNo.jpeg","seoabout":"CNBX Pharmaceuticals is developing a platform that leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based cancer ther...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Cannabis","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","classificationName":"sectorclassification"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Medical Cannabis#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Medical Cannabis#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Medical Cannabis","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Medical Cannabis"}]}]}],"targetCustomer":[],"coreTechnology":[]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Cannabis","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[],"targetCustomerClassifications":[],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Medical Cannabis"],"coreTechnology":[],"targetCustomer":[]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"DovXt9Dl6cYaCLeAehZL3PWXEnbjVKoEF7YF6vRSEcNrTv92xPLx6I","date":"Sep 2017","amount":"Undisclosed","source":"","ticker":"CNBX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"OTC","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCI2oTbCgw","stockexchange_logokey":"$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}